ACG Metals Limited (LON:ACG)

Intra-Cellular Therapies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	7.73	1.14
Cash & Short-Term Investments	7.73	1.14
Cash Growth	577.01%	-
Other Receivables	5.99	-
Receivables	5.99	-
Inventory	5.93	-
Prepaid Expenses	0.48	0.16
Total Current Assets	20.13	1.3
Property, Plant & Equipment	34.51	-
Goodwill	34.25	-
Other Intangible Assets	79.75	-
Other Long-Term Assets	0.23	-
Total Assets	168.88	1.3
Accounts Payable	14.12	0.18
Accrued Expenses	5.02	0.08
Short-Term Debt	31.64	-
Current Income Taxes Payable	4.42	-
Current Unearned Revenue	0.42	-
Other Current Liabilities	18.18	1.24
Total Current Liabilities	73.81	1.5
Long-Term Unearned Revenue	0.09	-
Long-Term Deferred Tax Liabilities	14.88	-
Other Long-Term Liabilities	33.53	-
Total Liabilities	122.3	1.5
Common Stock	72.61	1.59
Retained Earnings	-35.06	-22.5
Comprehensive Income & Other	9.03	20.72
Shareholders' Equity	46.58	-0.19
Total Liabilities & Equity	168.88	1.3
Total Debt	31.64	-
Net Cash (Debt)	-23.91	1.14
Net Cash Per Share	-2.88	0.64
Filing Date Shares Outstanding	18.97	1.8
Total Common Shares Outstanding	18.97	1.8
Working Capital	-53.67	-0.19
Book Value Per Share	2.46	-0.11
Tangible Book Value	-67.43	-0.19
Tangible Book Value Per Share	-3.55	-0.11
Land	2.15	-
Buildings	2.33	-
Machinery	20.28	-
Construction In Progress	5.35	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.